Acarbose, an oral alpha-glucosidase inhibitor used to treat type 2 diabetes, is synthesized through a complex biosynthetic pathway involving the bacterium Actinoplanes utahensis [1]. This microorganism produces acarbose by secreting enzymes that break down starch and other complex carbohydrates into simpler sugars [1]. The process begins with the bacterium utilizing its own enzymes to modify starch-like compounds, ultimately leading to the formation of acarbose [1].
How is acarbose manufactured?
The commercial production of acarbose relies on the fermentation capabilities of Actinoplanes utahensis [1]. This bacterium is cultivated in a controlled environment where it naturally produces acarbose [1]. Following fermentation, the acarbose is isolated and purified from the fermentation broth through various chemical and physical processes to meet pharmaceutical standards [1].
When does acarbose patent exclusivity expire?
Patent exclusivity for acarbose has largely expired in many major markets. The original patents for acarbose were filed decades ago. For example, patents related to acarbose manufacturing processes and formulations may still be active, but the primary composition of matter patents have expired, allowing for generic production [2]. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals and would be a resource for specific patent timelines [2].
Can generic acarbose be made before patents expire?
Generic acarbose can be manufactured and marketed once the relevant patents protecting the drug's composition, manufacturing, and use have expired, and regulatory approval is obtained [3]. The expiration of patents typically opens the door for generic manufacturers to enter the market with bioequivalent versions of the drug.
What are the key enzymes in acarbose biosynthesis?
The biosynthesis of acarbose by Actinoplanes utahensis involves several key enzymes, including alpha-glucosidase, transglucosidase, and a unique alpha-amylase [1]. These enzymes work in concert to cleave and rearrange oligosaccharides, ultimately forming the acarbose molecule [1].
Who are the main manufacturers of acarbose?
Several pharmaceutical companies manufacture and market acarbose globally. The original innovator was Bayer, with its brand name Glucobay or Precose. Following patent expirations, numerous generic manufacturers have entered the market. Identifying all current manufacturers would require a comprehensive market analysis.
What are the risks associated with acarbose treatment?
Common side effects of acarbose include gastrointestinal issues such as diarrhea, flatulence, and abdominal pain, which are related to the undigested carbohydrates reaching the colon [4]. Less common risks can include liver enzyme elevations, though these are typically reversible upon discontinuation of the drug [4].
---
Sources:
[1] https://drugpatentwatch.com/blog/acarbose-biosynthetic-pathway-patent-application-us/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/understanding-nda-nda-process
[4] https://www.nhs.uk/medicines/acarbose/